Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.

Participants needed: 468
Trial details
Phase: Phase 3Age: 12+Biological sex: AllType: InterventionalSponsor: Syndax PharmaceuticalsUpdated: Jun 24, 2026Locations: 52
Eligibility criteria

Participants must have newly diagnosed and previously untreated AML and be candi... [+5]

Diagnosis of active acute promyelocytic leukemia. [+7]

Read more
Status: Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

Participants needed: 296
Trial details
Phase: Phase 2Age: 2+Biological sex: AllType: InterventionalSponsor: Syndax PharmaceuticalsUpdated: Jun 16, 2026Locations: 121
Eligibility criteria

Participants must be 2 years of age or older, at the time of signing the informe... [+14]

Has acute GVHD without manifestations of cGVHD. [+13]

Read more
Status: Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.

Participants needed: 447
Trial details
Phase: Phase 1, Phase 2Age: 30+Biological sex: AllType: InterventionalSponsor: Syndax PharmaceuticalsUpdated: Mar 18, 2026Locations: 57
Eligibility criteria

Arm A: Participants not receiving any strong CYP3A4 inhibitor/inducers or flucon... [+25]

Diagnosis of active acute promyelocytic leukemia. [+12]

Read more